The Movember Foundation's GAP3 cohort: a profile of the largest global prostate cancer active surveillance database to date
Autor: | Bruinsma, Sophie M., Zhang, Liying, Roobol, Monique J., Bangma, Chris H., Steyerberg, Ewout W., Nieboer, Daan, Van Hemelrijck, Mieke, Trock, Bruce, Ehdaie, Behfar, Carroll, Peter, Filson, Christopher, Kim, Jeri, Morgan, Todd, Klotz, Laurence, Pickles, Tom, Hyndman, Eric, Moore, Caroline M., Gnanapragasam, Vincent, Dasgupta, Prokar, Villers, Arnauld, Rannikko, Antti, Valdagni, Riccardo, Perry, Antoinette, Hugosson, Jonas, Rubio-Briones, Jose, Bjartell, Anders, Hefermehl, Lukas, Lui Shiong, Lee, Frydenberg, Mark, Kakehi, Yoshiyuki, Ha Chung, Byung, van der Kwast, Theo, Obbink, Henk, van der Linden, Wim, Hulsen, Tim, de Jonge, Cees, Kattan, Mike, Xinge, Ji, Muir, Kenneth, Lophatananon, Artitaya, Fahey, Michael, Guo, Wei, Milan, Tanya, Benfante, Nicole, Cowan, Janet, Patil, Dattatraya, Sanford, Rachel, Kim, Tae Kyung, Mamedov, Alexandre, Santaolalla, Aida |
---|---|
Přispěvatelé: | Urology, Public Health |
Rok vydání: | 2018 |
Předmět: |
Male
Time Factors Databases Factual Urology medicine.medical_treatment #PCSM 030232 urology & nephrology computer.software_genre Global Health Risk Assessment Time-to-Treatment Cohort Studies 03 medical and health sciences Prostate cancer 0302 clinical medicine Quality of life SDG 3 - Good Health and Well-being evidence-based Interquartile range Medicine Humans Cumulative incidence Public Health Surveillance Watchful Waiting Early Detection of Cancer Aged Aged 80 and over adenocarcinoma Database business.industry Prostatic Neoplasms Middle Aged medicine.disease Prognosis Discontinuation #ProstateCancer Charities 030220 oncology & carcinogenesis Cohort Disease Progression business Men's Health guideline computer Watchful waiting Cohort study |
Zdroj: | BJU International, 121(5), 737-744. Wiley-Blackwell Publishing Ltd Bruinsma, S M, Zhang, L, Roobol, M J, Bangma, C H, Steyerberg, E W, Nieboer, D, Van Hemelrijck, M, Trock, B, Ehdaie, B, Carroll, P, Filson, C, Kim, J, Morgan, T, Klotz, L, Pickles, T, Hyndman, E, Moore, C M, Gnanapragasam, V, Dasgupta, P, Villers, A, Rannikko, A, Valdagni, R, Perry, A, Hugosson, J, Rubio-Briones, J, Bjartell, A, Hefermehl, L, Lui Shiong, L, Frydenberg, M, Kakehi, Y, Ha Chung, B, van der Kwast, T, Obbink, H, van der Linden, W, Hulsen, T, de Jonge, C, Kattan, M, Xinge, J, Muir, K, Lophatananon, A, Fahey, M, Guo, W, Milan, T, Benfante, N, Cowan, J, Patil, D, Sanford, R, Kim, T K & Mamedov, A & Santaolalla, A 2018, ' The Movember Foundation's GAP3 cohort : a profile of the largest global prostate cancer active surveillance database to date ', BJU International, vol. 121, no. 5, pp. 737-744 . https://doi.org/10.1111/bju.14106 |
ISSN: | 1464-4096 |
Popis: | Objectives: The Movember Foundation launched the Global Action Plan Prostate Cancer Active Surveillance (GAP3) initiative to create a global consensus on the selection and monitoring of men with low-risk prostate cancer (PCa) on active surveillance (AS). The aim of this study is to present data on inclusion and follow-up for AS in this unique global AS database. Patients and Methods: Between 2014 and 2016, the database was created by combining patient data from 25 established AS cohorts worldwide (USA, Canada, Australasia, UK and Europe). Data on a total of 15 101 patients were included. Descriptive statistics were used to report patients' clinical and demographic characteristics at the time of PCa diagnosis, clinical follow-up, discontinuation of AS and subsequent treatment. Cumulative incidence curves were used to report discontinuation rates over time. Results: At diagnosis, the median (interquartile range [IQR]) patient age was 65 (60–70) years and the median prostate-specific antigen level was 5.4 (4.0–7.3) ng/mL. Most patients had clinical stage T1 disease (71.8%), a biopsy Gleason score of 6 (88.8%) and one tumour-positive biopsy core (60.3%). Patients on AS had a median follow-up time of 2.2 (1.0–5.0) years. After 5, 10 and 15 years of follow-up, respectively, 58%, 39% and 23% of patients were still on AS. The current version of GAP3 has limited data on magnetic resonance imaging (MRI), quality of life and genomic testing. Conclusions: GAP3 is the largest worldwide collaboration integrating patient data from men with PCa on AS. The results will allow individual patients and clinicians to have greater confidence in the personalized decision to either delay or proceed with active treatment. Longer follow-up and the evaluation of MRI, new genomic markers and patient-related outcomes will result in even more valuable data and eventually in better patient outcomes. |
Databáze: | OpenAIRE |
Externí odkaz: |